<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02535975</url>
  </required_header>
  <id_info>
    <org_study_id>4-2014-0706</org_study_id>
    <nct_id>NCT02535975</nct_id>
  </id_info>
  <brief_title>The Effects of Metformin in Patients With Mild Graves' Ophthalmopathy</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>Yonsei University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Yonsei University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a prospective, randomized, double-blind, placebo-controlled study about the effect of
      metformin in patients with mild Graves' ophthalmopathy. Eighty patients with mild
      ophthalmopathy will be included. Each patient will be given either metformin (500mg PO three
      times a day) or placebo ( PO three times a day ) for 6 months and then followed for 6 months
      after withdrawal of treatment.
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>December 2014</start_date>
  <completion_date type="Anticipated">June 2017</completion_date>
  <primary_completion_date type="Anticipated">June 2017</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change of Clinical Activity Score (CAS) score</measure>
    <time_frame>At 0, 6 and 12 months</time_frame>
    <description>Comparison of CAS scores before and after treatment in each arm and an inter-arm</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change of NOSPECS score</measure>
    <time_frame>At 0, 6 and 12 months</time_frame>
    <description>Comparison of NOSPECS scores before and after treatment in each arm and an inter-arm.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>adverse events</measure>
    <time_frame>At 0, 6 and 12 months</time_frame>
    <description>Comparison of adverse events rate in each arm and an inter-arm.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life questionnaires (GO-QoL)</measure>
    <time_frame>At 0, 6 and 12 months</time_frame>
    <description>Comparison of Graves' ophthalmopathy Quality of life questionnaire (GO-QOL) scores before and after treatment in each arm and an inter-arm.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">80</enrollment>
  <condition>Mild Graves' Ophthalmopathy</condition>
  <arm_group>
    <arm_group_label>Metformin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Metformin 500mg PO three times a day for 24 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo tab. PO three times a day for 24 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Metformin</intervention_name>
    <description>Tablets metformin 500 mg PO three times a day for 24 weeks</description>
    <arm_group_label>Metformin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Tablets placebo PO three times a day for 24 weeks</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Age 18-80 years

          2. Patients should not have diabetes (HbA1c level at screening should be lower than 6.5)

          3. Mild Graves' ophthalmopathy according to EUGOGO statement.

          4. Clinical activity score lower than 4

          5. Being euthyroid for at least 2 month before the enrollment

          6. No previous specific therapy for GO in 6 month before the enrollment except for local
             measures (e.g. eye drops)

        Exclusion Criteria:

          1. Moderate-severe Graves' ophthalmopathy

          2. Clinical activity score â‰¥ 4

          3. Contraindication for metformin use as following: renal dysfunction (creatinine level
             should be within normal range), liver dysfunction (AST and ALT levels should be within
             normal range), severe concomitant illness

          4. Pregnant women

          5. Current use of metformin or containing preparations

          6. Metformin intolerance

          7. Inability to comply with the study protocol
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Eun Jig Lee, MD, PhD</last_name>
    <phone>+82-2-2228-1983</phone>
    <email>ejlee432@yuhs.ac</email>
  </overall_contact>
  <location>
    <facility>
      <name>Endocrinology, Internal Medicine, Yonsei University College of Medicine</name>
      <address>
        <city>Seoul</city>
        <zip>03722</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Eun Jig Lee, MD</last_name>
      <phone>+82-2-2228-1983</phone>
      <email>ejlee432@yuhs.ac</email>
    </contact>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>August 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 12, 2015</study_first_submitted>
  <study_first_submitted_qc>August 26, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 31, 2015</study_first_posted>
  <last_update_submitted>August 26, 2015</last_update_submitted>
  <last_update_submitted_qc>August 26, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 31, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Eye Diseases</mesh_term>
    <mesh_term>Graves Ophthalmopathy</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Metformin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

